Clinical and pharmacokinetic/dynamic outcomes of prolonged infusions of beta-lactam antimicrobials: An overview of systematic reviews
Open accessThe DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
Objective: This overview of reviews aims to map and compare of objectives, methods, and findings of existing systematic reviews to develop a greater understanding of the information available about prolonged beta-lactam infusions in hospitalized patients with infection. Design: Overview of systematic reviews. Data sources: Medline, Embase, PROSPERO and the Cochrane Library were systematically searched from January, 1990 to June, 2019 using a peer reviewed search strategy. Grey literature was also searched for relevant reviews. Eligibility criteria for selecting reviews: Systematic reviews were sought that compared two or more infusion strategies for intravenous beta-lactam antimicrobials and report clinical cure or mortality. Populations of included reviews were restricted to hospitalized patients with infection, without restrictions on age, infection type, or disease. Data extraction and analysis: Abstract screening, data extraction, quality and risk of bias assessment were conducted by two independent reviewers. Overlap between reviews was assessed using a modified corrected covered area. Overview findings are reported in accordance with Cochrane’s recommendation for overview conduct. Clinical outcomes extracted included survival, clinical cure, treatment failure, microbiological cure, length of stay, adverse events, cost, and emergence of resistance. Results: The search strategy identified 3327 unique citations from which 21 eligible reviews were included. Reviews varied by population, intervention and outcomes studied. Between reviews, overlap of primary studies was generally high, methodologic quality generally low and risk of bias variable. Nine of 14 reviews that quantitatively evaluated mortality and clinical cure identified a benefit with prolonged infusions of beta lactams when compared with intermittent infusions. Evidence of mortality and clinical cure benefit was greater among critically ill patients when compared to less sick patients and lower in randomized controlled trials when compared with observational studies. Conclusions: Findings from our review demonstrate a consistent and reproducible lack of harm with prolonged infusions of beta-lactam antibiotics with variability in effect size and significance of benefits. Despite 21 systematic reviews addressing prolonged infusions of beta-lactams, this overview supports the continued need for a definitive systematic review given variability in populations, interventions and outcomes in the current systematic reviews. Subsequent systematic reviews should have more rigorous and transparent methods, only include RCTs and evaluate the proposed benefits found in various subgroup-analyses—i.e. high risk of mortality. Trial registration: Prospero registry, CRD42019117118.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






![Fig 7 Effect of prolonged versus intermittent infusions of beta-lactam antimicrobials on clinical cure. *Lee 2017 –Did not report event rates. RR was therefore not converted to OR. **Roberts 2016 –individual patient data meta-analysis. ***Chant 2013 –reported treatment failure. RR = 0.60 [0.40–0.87], I2 = 69%. Results were inverted to represent clinical cure or success.](https://figures.cochat.ai/paper-figures/b6a76ab044a84298af1a15ee707e2a44/clinical-and-pharmacokinetic-dynamic-outcomes-of-prolonged-infusions-of-beta-figure-7.jpg)














Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“when low overlap was found between reviews with inconsistent and discordant findings, discrepancies were most often attributed to differences in scope or differences in dates of review publication.”
From Managing overlap of primary study results across systematic reviews: practical considerations for authors of overviews of reviews (2021) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Twenty-one reviews involving 71 primary studies were included.”
From Managing overlap of primary study results across systematic reviews: practical considerations for authors of overviews of reviews (2021) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Thabet et al. found that overlap was moderate to high for each outcome and percentage of unique references ranged from 38 to 78%.”
From Managing overlap of primary study results across systematic reviews: practical considerations for authors of overviews of reviews (2021) · cites this paper as [26]
In the citing paper
“when two reviews had similar findings and low overlap for a particular outcome, the results of the reviews could be trusted despite differences in PICO scope (i.e. different populations or beta-lactams) or differences in dates of publication”
From Managing overlap of primary study results across systematic reviews: practical considerations for authors of overviews of reviews (2021) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PRISMA-P Group, Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015) · Systematic Reviews · doi:10.1186/2046-4053-4-1 · Cited by 26,223 · cited 1×
“Methods This overview of reviews was guided by the Cochrane Handbook [37] on methods for overviews of reviews, the PRISMA guidelines for reporting of systematic reviews [38, 39] and PRIO-harms checklist [40].”
MethodShamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A., & the PRISMA-P Group (2015) · BMJ · doi:10.1136/bmj.g7647 · Cited by 13,120 · cited 1×
“Methods This overview of reviews was guided by the Cochrane Handbook [37] on methods for overviews of reviews, the PRISMA guidelines for reporting of systematic reviews [38, 39] and PRIO-harms checklist [40].”
MethodShea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., Moher, D., Tugwell, P., Welch, V., Kristjansson, E., et al. (2017) · BMJ · doi:10.1136/bmj.j4008 · Cited by 10,636 · cited 1×
“Quality assessment of each included review was conducted using the AMSTAR-2 tool (Assessing the Methodological Quality of Systematic Reviews), and risk of bias of assessments were performed using with the ROBIS tool (Risk of Bias in Systematic Reviews); all assessments were performed by one reviewer (PT) and verified…”
MethodAngus, D. C., Linde-Zwirble, W. T., Lidicker, J., Clermont, G., Carcillo, J., & Pinsky, M. R. (2001) · Critical Care Medicine · doi:10.1097/00003246-200107000-00002 · Cited by 8,503 · cited 1×
“This is particularly true of patients with sepsis and the critically ill [1, 2].”
BackgroundPRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement
McGowan, J., Sampson, M., Salzwedel, D. M., Cogo, E., Foerster, V., & Lefebvre, C. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.01.021 · Cited by 5,700 · cited 1×
“Searching the literature A systematic search strategy for Medline, Embase, and the Cochrane Library, was created by an experienced information specialist and reviewed by a second information specialist using the PRESS criteria (S1 Fig) [41].”
MethodSurviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002255 · Cited by 3,652
ROBIS: A new tool to assess risk of bias in systematic reviews was developed
Whiting, P., Savović, J., Higgins, J. P. T., Caldwell, D. M., Reeves, B. C., Shea, B., Davies, P., Kleijnen, J., & Churchill, R. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.06.005 · Cited by 2,272
Increasing value and reducing waste in research design, conduct, and analysis
Ioannidis, J. P. A., Greenland, S., Hlatky, M. A., Khoury, M. J., Macleod, M. R., Moher, D., Schulz, K. F., & Tibshirani, R. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62227-8 · Cited by 1,597 · cited 1×
“Poor quality conduct of reviews impedes decision making and represents waste in use of research dollars [63, 64].”
BackgroundReducing waste from incomplete or unusable reports of biomedical research
Glasziou, P., Altman, D. G., Bossuyt, P., Boutron, I., Clarke, M., Julious, S., Michie, S., Moher, D., & Wager, E. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62228-x · Cited by 1,319 · cited 1×
“Poor quality conduct of reviews impedes decision making and represents waste in use of research dollars [63, 64].”
BackgroundSystematic review finds overlapping reviews were not mentioned in every other overview
Pieper, D., Antoine, S.-L., Mathes, T., Neugebauer, E. A. M., & Eikermann, M. (2014) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.11.007 · Cited by 1,318 · cited 14×
“Overlap of included studies was slight, with a https://doi.org/10.1371/journal.pone.0244966.g012 PLOS ONE | https://doi.org/10.1371/journal.pone.0244966 January 22, 2021 18 / 35 CCA of 4.8% (acknowledging that the review by Vardakas et al. did not identify the trials they included in the evaluation of this outcome) [2…”
MethodInfluential
Research works printed but not linked: 2
- Pollock M FR, Becker LA, Pieper D, Hartling L. Chapter V: Overviews of Reviews. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. www.training.cochrane.org/handbook.
- Centre for Reviews and D, 2015, Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis (Provisional abstract), Database of Abstracts of Reviews of Effects
Cited by
Lunny, C., Pieper, D., Thabet, P., & Kanji, S. (2021) · BMC Medical Research Methodology · doi:10.1186/s12874-021-01269-y · Cited by 252
Self-citationOptimizing antibiotic therapies to reduce the risk of bacterial resistance
Bassetti, S., Tschudin-Sutter, S., Egli, A., & Osthoff, M. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.01.029 · Cited by 196
Dulhunty, J. M., Brett, S. J., De Waele, J. J., Rajbhandari, D., Billot, L., Cotta, M. O., Davis, J. S., Finfer, S., Hammond, N. E., Knowles, S., et al. (2024) · JAMA · doi:10.1001/jama.2024.9779 · Cited by 171
Timing of antibiotic therapy in the ICU
Kollef, M. H., Shorr, A. F., Bassetti, M., Timsit, J.-F., Micek, S. T., Michelson, A. P., & Garnacho-Montero, J. (2021) · Critical Care · doi:10.1186/s13054-021-03787-z · Cited by 161
Suicidality risk after using cannabis and cannabinoids: An umbrella review
Shamabadi, A., Ahmadzade, A., Pirahesh, K., Hasanzadeh, A., & Asadigandomani, H. (2023) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2023.2231466 · Cited by 51
“A citation matrix was also provided to represent overlap visually (Thabet et al. 2021).”
BackgroundSilva, C. M., Baptista, J. P., Santos, I., & Martins, P. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106569 · Cited by 39
Roberts, J. A., Croom, K., & Adomakoh, N. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2184347 · Cited by 34
Hyun, D., Seo, J., Lee, S. Y., Ahn, J. H., Hong, S., Lim, C., Koh, Y., & Huh, J. W. (2022) · Antibiotics · doi:10.3390/antibiotics11111508 · Cited by 21
Kanji, S., Roger, C., Taccone, F. S., & Müller, L. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2858 · Cited by 21
Self-citationEmpirical decision-making for antimicrobial therapy in critically ill patients
Ippolito, M., & Cortegiani, A. (2023) · BJA Education · doi:10.1016/j.bjae.2023.09.001 · Cited by 19
Sember, A. M., LoFaso, M. E., & Lewis, S. J. (2022) · Journal of Critical Care · doi:10.1016/j.jcrc.2022.154011 · Cited by 15
Dräger, S., von Rotz, M., Labhardt, N. D., Siegemund, M., Rentsch, K., Osthoff, M. F., & Franzeck, F. C. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad143 · Cited by 19
“To achieve this goal, prolonged infusion of β -lactam antibi - otics should be favored over intermittent bolus application because this mode of administration contributes to improved PKPD and may be associated with decreased mortality in critically ill patients [15, 21–23].”
Shappell, C. N., Klompas, M., & Rhee, C. (2023) · JAMA · doi:10.1001/jama.2023.6483 · Cited by 11
Early Empirical Use of Broad-Spectrum Antibiotics in Sepsis
Chang, J. L., Pearson, J. C., & Rhee, C. (2022) · Current Infectious Disease Reports · doi:10.1007/s11908-022-00777-2 · Cited by 13
Tait, J. R., Bilal, H., Rogers, K. E., Lang, Y., Kim, T., Zhou, J., Wallis, S. C., Bulitta, J. B., Kirkpatrick, C. M. J., Paterson, D. L., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11010101 · Cited by 8
“Over time, the application of a target of 100% f T>MIC has become more prevalent for achievement of optimal bacterial killing and resistance suppression for difficult-to-treat pathogens and critically ill patients [49,50].”
BackgroundThabet, P., Kanji, S., Pieper, D., & Lunny, C. (2022) · Research Synthesis Methods · doi:10.1002/jrsm.1586 · Cited by 7
“Whilst conducting an overview of systematic reviews on the clinical and pharmacokinetic/pharmacodynamics outcomes of prolonged infusions of beta-lactam antimicrobials, our research team used the corrected-covered area (CCAs) to describe overlap between included systematic reviews.(4) In our opinion, this single summar…”
MethodSelf-citationKatchali, M., Onyango, E. R., Tonnang, H. E. Z., Tanga, C. M., Beesigamukama, D., & Senagi, K. (2025) · PLoS ONE · doi:10.1371/journal.pone.0292418 · Cited by 9
Minichmayr, I. K., Kappetein, S., Brill, M. J. E., & Friberg, L. E. (2022) · Antibiotics · doi:10.3390/antibiotics11081036 · Cited by 6
“While the carbapenem antibiotic meropenem, for instance, is approved as 15–30 min infusions, 3-h infusions up to continuous infusions are commonly used [3,4].”
BackgroundKonkayev, A. K., Kadralinova, A., Azimova, B., Tazhibaeva, D., Yeltayeva, A. A., & Konkayeva, M. E. (2024) · Medicina · doi:10.3390/medicina60060929 · Cited by 5
“But studies suggest that long-term or continuous infusions of carbapenems are associated with similar mortality rates as conventional intermittent infusions but may have other benefits, such as clinical cure and microbiological success, as evidenced by limited data [11–13].”
BackgroundRagonnet, G., Guilhaumou, R., Hanafia, O., Néant, N., Denante, S., Vanel, N., Honoré, S., & Michel, F. (2024) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2024.101354 · Cited by 5
Liu, Y., Wang, C., Wang, Q., Zhang, Q., Ning, S., & Zhang, Q. (2024) · Integrative Medicine Research · doi:10.1016/j.imr.2024.101088 · Cited by 4
Collignon, C., Gana, I., Benaboud, S., Toubiana, J., Castelle, M., Oualha, M., & de Marcellus, C. (2021) · Therapies · doi:10.1016/j.therap.2021.10.003 · Cited by 4
Rasmussen, H. C., Hanberg, P., Knudsen, M., Tøstesen, S. K., Jørgensen, A. R., Petersen, E. K., Öbrink‐Hansen, K., Søballé, K., Stilling, M., & Bue, M. (2023) · Antibiotics · doi:10.3390/antibiotics12030577 · Cited by 4
“However, the immediate clinical advantages remain largely unclear [26,30].”
BackgroundMethodGates, M., Gates, A., Pieper, D., Fernandes, R., Tricco, A., Moher, D., Brennan, S. E., Li, T., Pollock, M., Lunny, C., et al. (2022) · doi:10.31222/osf.io/23b6j · Cited by 3
Kovačević, Z., Čudina, N., Pećin, M., Samardžija, M., Pajić, M., Pintarić, S., Vlahek, I., Ružić, Z. N., Vračar, V., Galić, I., et al. (2024) · Animals · doi:10.3390/ani14182736 · Cited by 4
“…it is well established that suboptimal antibiotic concentrations are linked to poor treatment outcomes, can exert non-lethal selective pressure, and may lead to the amplification of resistant bacteria [29–31], there is some uncertainty regarding this issue among students before the symposium.”
BackgroundWas ist gesichert in der Therapie der Sepsis? Ein Update
Hillebrand, U., Rex, N., Seeliger, B., Stahl, K., & Schenk, H. J. (2024) · Die Innere Medizin · doi:10.1007/s00108-024-01794-0 · Cited by 1
Carson, A. A., Bowker, K. E., Attwood, M., Noel, A. R., & MacGowan, A. P. (2024) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlae108
Lunny, C., Pieper, D., Thabet, P., & Kanji, S. (2021) · Figshare · doi:10.6084/m9.figshare.14926906
Self-citationLiu, J., Zhu, J. F., Liang, G., Yang, Y., Yu, L., Zhao, Y., & Yu, Z. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1838789
“Extensive antimicrobial literature further supports that prolonged infusions regimens enhance PK/PD target attainment for time-dependent agents, without requiring higher peak levels (Thabet et al., 2021).”
Metadata
- Authors
- Thabet, P., Joshi, A., MacDonald, E., Hutton, B., Cheng, W., Stevens, A., & Kanji, S.
- Affiliations
- Ottawa Hospital (CA)
- University of Waterloo (CA)
- University of Ottawa (CA)
- Ottawa Hospital Research Institute (CA)
- McMaster University (CA)
- Corresponding author
- Kanji, Salmaan
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-01-22
- Volume
- 16
- Issue
- 1
- Pages
- e0244966
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC7822342
- OpenAlex
- W3125727119
- Cited by
- 29
- References
- 62
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 7 · 2023: 7 · 2022: 9 · 2021: 4
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- beta-lactam antibiotics, prolonged infusion, intermittent infusion, intravenous antibiotic administration, mortality, clinical cure, microbiological cure, length of hospital stay, antimicrobial resistance, critically ill patients, pharmacokinetics, pharmacodynamics
- MeSH terms
- Systematic Reviews as Topic, Anti-Bacterial Agents, Bacterial Infections, Humans, Infusions, Intravenous, Treatment Outcome, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.